SRC and cancer: In contrast to the aforementioned studies, a recent paper has shown that Src inhibitors—dasatinib or saracatinib—not only failed to eliminate cancer stem cells in tumorspheres but also increased the expression of ALDH1A1, SOX2, OCT4, and NANOG.